{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:21:36Z","timestamp":1768443696995,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtocrr.2025.100918","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:36:06Z","timestamp":1760074566000},"page":"100918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC"],"prefix":"10.1016","volume":"7","author":[{"given":"Beatriz Jimenez","family":"Munarriz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameena","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina","family":"Hueniken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devalben","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luna","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawson","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2025.100918_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jtocrr.2025.100918_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.jtocrr.2025.100918_bib3","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2025.100918_bib4","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer","volume":"36","author":"Solomon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2025.100918_bib6","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2025.100918_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2025.100918_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2025.100918_bib10","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2025.100918_bib11","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib12","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2025.100918_bib13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jtho.2024.01.013","article-title":"Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive NSCLC: interim analysis of a randomized, open-label, Phase 3 study (INSPIRE)","volume":"19","author":"Shi","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41392-023-01538-w","article-title":"Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtocrr.2025.100918_bib15","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.3390\/cancers13153704","article-title":"Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: a systematic review and network meta-analysis","volume":"13","author":"Ando","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2025.100918_bib16","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the Phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jtho.2018.12.014","article-title":"Natural history and factors associated with overall survival in Stage IV ALK-rearranged non-small cell lung cancer","volume":"14","author":"Pacheco","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cllc.2022.09.007","article-title":"Real-world treatment sequencing, toxicities, health utilities, and survival outcomes in patients with advanced ALK-rearranged non-small-cell lung cancer","volume":"24","author":"Schmid","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100918_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/CMAR.S393729","article-title":"Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country","volume":"15","author":"Poh","year":"2023","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jtocrr.2025.100918_bib20","article-title":"Real-world treatment and outcomes in ALK-rearranged NSCLC: results from a Large U.S.-based database","volume":"5","author":"Chazan","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2025.100918_bib21","doi-asserted-by":"crossref","first-page":"21903","DOI":"10.18632\/oncotarget.15746","article-title":"Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study","volume":"8","author":"Duruisseaux","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtocrr.2025.100918_bib22","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3332\/ecancer.2024.1667","article-title":"Real world study of safety and efficacy of lorlatinib as second line and beyond in ALK-rearranged advanced non-small cell lung cancer patients in India - a multicentre chart review study (ROSELAND)","volume":"18","author":"Biswas","year":"2024","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.jtocrr.2025.100918_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101560","article-title":"Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors","volume":"8","author":"Zhou","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtocrr.2025.100918_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.11.004","article-title":"Safety issues with the ALK inhibitors in the treatment of NSCLC: a systematic review","volume":"134","author":"Kassem","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11523-023-00973-7","article-title":"ALK inhibitor treatment patterns and outcomes in Real-world patients with ALK-positive non-small-cell lung cancer: a retrospective cohort study","volume":"18","author":"Wang","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107319","article-title":"Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: systematic review and network meta-analysis","volume":"184","author":"Luo","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100918_bib27","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.3390\/cancers15133422","article-title":"Evaluation of efficacy of ALK inhibitors according to body mass index in ALK rearranged NSCLC patients-a retrospective observational study","volume":"15","author":"Siringo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2025.100918_bib28","doi-asserted-by":"crossref","first-page":"22137","DOI":"10.18632\/oncotarget.25154","article-title":"Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer","volume":"9","author":"Costa","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtocrr.2025.100918_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135521","article-title":"Crizotinib-induced abnormal signal processing in the retina","volume":"10","author":"Ishii","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtocrr.2025.100918_bib30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical management of adverse events associated with lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jtocrr.2025.100918_bib31","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s00204-023-03524-1","article-title":"Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism","volume":"97","author":"Liu","year":"2023","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib32","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.1016\/j.jtho.2022.07.839","article-title":"EP08.02-156 real-world treatment patterns and impact of comorbidity burden on treatment duration for patients with ALK+ NSCLC in the US","volume":"17","author":"Wan","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib33","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jgo.2018.09.008","article-title":"Treatment of older patients with advanced non-small cell lung cancer: a challenge","volume":"10","author":"Decoster","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib34","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2023.03.020","article-title":"Analysis of serious weight gain in patients using alectinib for ALK-positive lung cancer","volume":"18","author":"de Leeuw","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib35","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/psp4.12702","article-title":"Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"10","author":"Hsu","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib36","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/1759-7714.13018","article-title":"Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study","volume":"10","author":"Ono","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtocrr.2025.100918_bib37","article-title":"Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment","volume":"40","author":"Tanaka","year":"2024","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.jtocrr.2025.100918_bib38","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/j.1875-9114.2012.01108.x","article-title":"Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults","volume":"32","author":"Pai","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtocrr.2025.100918_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70224","article-title":"Inter-ethnic differences in the efficacy and safety of tyrosine kinase inhibitors used in oncology: insights from Phase 3 clinical trials","volume":"18","author":"Kyriacou","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtocrr.2025.100918_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jtho.2024.11.025","article-title":"Sex and common germline variants affect the toxicity profile and pharmacokinetics of alectinib: a nationwide cohort study in patients with ALK-positive NSCLC","volume":"20","author":"Heersche","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000344","article-title":"Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?","volume":"3","author":"Pinto","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtocrr.2025.100918_bib42","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/cncr.28089","article-title":"Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients","volume":"119","author":"Weickhardt","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2025.100918_bib43","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/cncr.35293","article-title":"Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced non-small cell lung cancer","volume":"130","author":"Vita","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2025.100918_bib44","article-title":"Revisiting a lower starting dose of alectinib in ALK-positive non-small cell lung cancer","volume":"27","author":"Sacdalan","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.jtocrr.2025.100918_bib45","doi-asserted-by":"crossref","first-page":"S644","DOI":"10.1016\/j.jtho.2024.09.1215","article-title":"EP.12B.10 patterns and clinical impact of alectinib dose reduction in patients with ALK-positive non- small cell lung cancer (NSCLC)","volume":"19","author":"To","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100918_bib46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtocrr.2025.100918_bib47","article-title":"Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification","volume":"196","author":"Igawa","year":"2024","journal-title":"Lung Cancer"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325001365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325001365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:50:54Z","timestamp":1768405854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364325001365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666364325001365"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100918","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer\u00e9","name":"copyright","label":"Copyright"}],"article-number":"100918"}}